Navigation Links
Stemedica Announces the Appointment of Dr. Michael Bayer as Director, Medical Services
Date:1/30/2009

Stemedica Cell Technologies, Inc., a leader in adult stem cell production, announced today the appointment of Michael Bayer, MD, as Director, Medical Services. Dr. Bayer will be responsible for developing pre-clinical and clinical trial protocols for use by research centers conducting pre-clinical and clinical trials using Stemedica products.

San Diego, CA (PRWEB) January 30, 2009 -- Stemedica Cell Technologies, Inc., a leader in adult stem cell production, announced today the appointment of Michael Bayer, MD, as Director, Medical Services. Dr. Bayer will be responsible for developing pre-clinical and clinical trial protocols for use by research centers conducting pre-clinical and clinical trials using Stemedica products.

An Orthopedic Surgeon and Clinician, Dr. Bayer's specialty is Translational Medicine - taking laboratory research and results and applying them in new patient treatments.    World renowned for inventing an arthroscopic surgical technique for repairing rotator cuff injuries, Dr. Bayer has worked with major clinical research institutions and physicians around the world to bring new technology safely and successfully into the medical marketplace.

Dr. Bayer's new role at Stemedica was warmly welcomed by Dr. Nikolai Tankovich, President, Chief Medical Officer of Stemedica. "I am very impressed with Dr. Bayer's long track record of translating laboratory results to practical surgery and treatments. Dr. Bayer is a brilliant surgeon and clinician and we feel very fortunate to have attracted his interest and to have brought about this significant appointment. I am looking forward to working with him to advance our work," said Dr. Tankovich.

For the past year, Dr. Bayer has been involved in a Fellowship Study Program with Dr. Nikolay Mironov, the world's foremost adult stem cell clinician, and with Dr. Alex Kharazi, Stemedica's Vice President - R&D and Manufacturing.

"My interest in Stemedica and their technology quickly deepened when I became aware of the difference that treatments were having on the quality of life for patients participating in clinical trials. After a year of study and interaction with Drs. Mironov and Kharazi, I believe I have as strong a knowledge of stem cell effects in research and medical applications. I was so inspired by what I had learned and witnessed first hand from clinical outcomes of patients participating in overseas clinical studies that I asked Stemedica if there was any way I could support the company with my translational knowledge and experience. In my new role, I know I will be making a difference in a very important and evolving area of medicine. That really matters to me," said Dr. Michael Bayer.

"We realized from the first day we met Dr. Bayer that he had the experience in medical technology innovation and in translational medicine that would be valuable to a company like ours. After his fellowship with Drs. Mironov and Kharazi we knew he had the commitment and first hand knowledge to support the ongoing development of our pre-clinical and clinical trials treatment protocols. We created the role for Dr. Bayer based on his interest in working with us and his desire to impact the quality of life possibilities for no-option patients. Stemedica is delighted to have Dr. Bayer join our team," said Maynard Howe, CEO and Vice Chairman at Stemedica.

In addition to his professional work, Dr. Bayer co-founded "The Free Wheelchair Mission", a non-profit that has delivered wheel chairs to over 370,000 people in some of the poorest countries worldwide. (www.freewheelchairmission.org)

About Stemedica Cell Technologies, Inc.
Stemedica Cell Technologies Inc. (http://www.stemedica.com) is a specialty biopharmaceutical company that is committed to the development and manufacture of best-in-class adult stem cells for use by approved research institutions and hospitals for pre-clinical and clinical studies. Within the United States, the Company is currently developing regulatory pathways for stroke, traumatic brain injury and wound repair. Outside the United States, Stemedica provides its adult stem cells to hospitals and research centers that are conducting studies under protocols approved by appropriate regulatory agencies. These studies are focused on the treatment of neurodegenerative disease, sight restoration and wound repair. Stemedica is headquartered in San Diego, California.

From more information regarding Stemedica Cell Technologies or the Dr. Michael Bayer appointment, contact Dave McGuigan at dmcguigan (at) stemedica (dot) com.

# # #

Read the full story at http://www.prweb.com/releases/stemedica/adult-stem-cell-research/prweb1936934.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Nektar Announces Retirement of Irwin Lerner from Board of Directors
2. Cardica Announces Fiscal 2009 Second Quarter Financial Results
3. Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
4. Omnitura Therapeutics Announces Private Placement Financing
5. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
6. Sangamo BioSciences Announces Fourth Quarter and Year-End 2008 Conference Call and Webcast
7. Helsinn Announces the Acquisition of Sapphire Therapeutics Inc., USA to Establish Helsinn Therapeutics (US) Inc.
8. Boston Scientific Announces Japanese Approval for TAXUS(R) Liberte(R) Drug-Eluting Stent System
9. Bion Announces PENNVEST Board Approves $7.8 Million Financing for Kreider Farms Dairy Project
10. Medarex Announces Allowance of Investigational New Drug Application for Companys First Antibody-Drug Conjugate, MDX-1203
11. XTL Biopharmaceuticals Announces Receipt of NASDAQ Notice of Delisting
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Stemedica Announces the Appointment of Dr. Michael Bayer as Director, Medical Services
(Date:6/23/2016)... Md. , June 23, 2016 A person ... from the crime scene to track the criminal down. ... the U.S. Food and Drug Administration (FDA) uses DNA evidence ... Sound far-fetched? It,s not. The FDA ... sequencing to support investigations of foodborne illnesses. Put as simply ...
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
(Date:6/23/2016)... BEACH, Calif. , June 23, 2016  Blueprint ... new biological discoveries to the medical community, has closed ... co-founder Matthew Nunez . "We have ... us with the capital we need to meet our ... will essentially provide us the runway to complete validation ...
(Date:6/23/2016)... ... 2016 , ... Velocity Products, a division of Morris Group, ... exclusively for Okuma CNC machining centers at The International Manufacturing Technology Show, IMTS, ... companies with expertise in toolholding, cutting tools, machining dynamics and distribution, Velocity SMART ...
Breaking Biology Technology:
(Date:6/2/2016)... 2, 2016   The Weather Company , an IBM ... an industry-first capability in which consumers will be able to ... ask questions via voice or text and receive relevant information ... Marketers have long sought an advertising solution that ... be personal, relevant and valuable; and can scale across millions ...
(Date:5/16/2016)... --  EyeLock LLC , a market leader of iris-based ... IoT Center of Excellence in Austin, Texas ... embedded iris biometric applications. EyeLock,s iris authentication ... with unmatched biometric accuracy, making it the most proven ... platform uses video technology to deliver a fast and ...
(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
Breaking Biology News(10 mins):